$EVFM News

Last published 1y ago

1y agoADTX EVFMAditxt Announces Termination of Arrangement Agreement With Appili TherapeuticsBusiness WireWill eliminate approximately $16M in closing obligations Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that it has
1y agoEVFMApproval of Phexxi, Nda #208352 (Labeling)FDA Approved DrugsApproval Date: 04/21/2025; Drug Name: Phexxi, Nda #208352; Active Ingredients: CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE; Company: Evofem Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 208352
1y agoEVFM WINTWindtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business UpdatesGlobeNewswireWARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for
1y agoEVFM WINTWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductGlobeNewswireWARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing
2y agoADTX EVFMEvofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1stGlobeNewswireSAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy
2y agoADTX EVFMAditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 ClosingBusiness WireEvofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising
2y agoADTX EVFMAditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women GloballyBusiness WireEvofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023; Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is
3y agoEVFMEvofem to Participate in the Virtual Investor Ask the CEO ConferencePR Newswire-- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET -- SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM) (the "Company")
3y agoEVFMEvofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents ExpirePR Newswire-- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 2033 -- SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM) today
3y agoEVFMEvofem Biosciences Successfully Amends S.P.A. with Institutional InvestorPR Newswire-- Investor withdraws March 2023 Notice of Default -- -- Notes are no longer convertible to shares of common stock, removing potential dilution from the previously-reserved over 240 million shares of common stock -- --
3y agoEVFMEvofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock ExchangePR NewswireSAN DIEGO, Aug. 22, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) (Evofem or the Company) today announced it has signed a confidential non-binding letter of intent (LOI) relating to a possible merger with a
3y agoEVFMEvofem Biosciences Announces Financial Results for the Second Quarter of 2023PR Newswire— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 68% — — Decreased
3y agoEVFMEvofem to Participate in the Virtual Investor Summer Spotlight SeriesPR Newswire-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12th at 4:00 p.m. ET -- SAN DIEGO, July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM) (the "Company")
3y agoEVFM EVFMDEvofem Biosciences Announces Financial Results for the First Quarter of 2023PR Newswire-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to positive EBITDA -- SAN
3y agoEVFM EVFMDEvofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023PR NewswireIncreased net product revenue more than 35% in the first quarter of 2023 vs. prior year quarter Reduced operating expenses more than 70% Decreased loss from operations more than 85% Reaffirms path to positive EDITDA SAN
3y agoEVFMEvofem Biosciences Announces 1-for-125 Reverse Stock SplitPR Newswire-- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to "EVFMD" for 20 business days, then revert to "EVFM" -- SAN DIEGO, May 17, 2023 /PRNewswire/ -- Evofem
3y agoEVFMEvofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate UpdatePR Newswire-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA break-even by year-end 2023
3y agoEVFMEvofem Appoints Ivy Zhang as Chief Financial Officer and SecretaryPR NewswireSAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief
3y agoEVFMEvofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization RequiredPR Newswire— Improves Phexxi coverage for more than 5.8 million New York lives — — Year-to-date, Evofem has gained Phexxi coverage for more than 22.1 million new lives — SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences,
3y agoEVFMEvofem Biosciences Announces Cost Reduction MeasuresPR Newswire– Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with corporate goal to reach cash flow break even by year-end 2023 – SAN DIEGO, March 21, 2023 /PRNewswire/ -- Evofem
3y agoEVFMEvofem Biosciences Appoints Interim Chief Financial OfficerPR NewswireSAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is
3y agoEVFMEvofem's Phexxi Contraceptive Gel Added to SimpleHealth Product OfferingPR Newswire-- Phexxi is the first and only hormone-free contraceptive offered by reproductive telehealth leader SimpleHealth to its patients -- SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM)
3y agoEVFMEvofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for PhexxiPR Newswire-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which
3y agoEVFMEvofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder ValuePR NewswireSAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and evaluate strategic
3y agoEVFMEvofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)PR Newswire-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- SAN DIEGO, Jan. 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) announced today that female telehealth leader
3y agoEVFMCostco Adds Phexxi® to Member Prescription ProgramPR NewswireSAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription
3y agoEVFMMultiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of WomenPR Newswire-- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states -- -- Largest commercial insurer in Michigan and a marquis university plan in Pennsylvania move Phexxi to Preferred formulary position
3y agoEVFMOTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022PR NewswireSAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter
4y agoEVFMEvofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in WomenPR NewswireSAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea
4y agoEVFMEvofem Biosciences Announces Uplisting to OTCQBPR NewswireSAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker symbol remains the sam
4y agoEVFMEvofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of MatterPR Newswire-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Patent Expected to Provide Protection for Phexxi into At Least 2033 -- SAN DIEGO, Sept. 23, 2022 /PRNewswire/ -- Evofem Bioscience
4y agoEVFMInventor of the Year Awarded to Developer of Phexxi®PR Newswire-- Dr. Donald Waller Honored by University of Illinois Chicago -- SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) is pleased to congratulate University of Illinois Chicago (UIC) Professor Emeritus Donald Waller, Ph.D., on hi
4y agoEVFMLarge Commercial Payer Adds Phexxi® to Formulary for Standard Plans NationwidePR Newswire-- One of the Largest Commercial Payers in the U.S. Expands Access to Phexxi® for Women Seeking FDA-Approved, Hormone-Free Contraception -- SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced another new i
4y agoEVFMEvofem Announces Successful Debt RestructuringPR Newswire-- Evofem Gains Forbearance from Debtholders for All Existing Matters-- SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced the successful restructuring of its debt, providing forbearance from its debtholde
4y agoEVFMEvofem Biosciences to Host Investor Call on Thursday, August 11, 2022PR Newswire-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: EVFM) (PRNewsfoto/E
4y agoEVFMTraders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra PelletierACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark
4y agoEVFMEvofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 GuidancePR Newswire-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter -- -- Reduced operating expense by 8% and improved loss from operations by 16% -- -- Completed registrational Phase 3 trial evaluatin
4y agoEVFMEvofem Biosciences Strengthens Board of DirectorsPR NewswireSAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a
4y agoEVFMEvofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in WomenPR Newswire-- Top-line readout of data expected in October 2022 -- -- U.S. regulatory submission planned for the first half of 2023 -- -- Phexxi may become the first-ever woman-controlled prophylactic for the prevention of chlamydia and gonorrhea -- SAN DIEGO
4y agoEVFMEvofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to IndividualsPR NewswireSAN DIEGO, July 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"),
4y agoEVFMEvofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022PR Newswire-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ende
4y agoEVFMEvofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry RecognitionPR NewswireEvocative direct-to-consumer (DTC) campaign has received 12 healthcare and communications industry awards to date and has recently been shortlisted for four more awards. The national campaign features Emmy® Award-winning spokeswoman and actress Annie
4y agoEVFMEvofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive CounselingPR NewswireSAN DIEGO, July 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United Sta
4y agoEVFMEvofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception ActPR NewswireSAN DIEGO, July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entit
4y agoEVFMEvofem Partners with a360 Media to Support Phexxi® Prescription GrowthPR NewswireAgreement with a360 Media Delivers Phexxi Branded Content in Leading Entertainment and Lifestyle Magazines a360 Media's Brands Include US Magazine, InTouch Weekly, and Woman's World 16% Lift in New Phexxi Prescriptions After First Two Weeks of Partne
4y agoEVFMPhexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive HealthPR NewswireSAN DIEGO, July 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) announced today that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally admi
4y agoEVFMEvofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTOPR NewswireSAN DIEGO, June 30, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Composit
4y agoEVFMEvofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®PR NewswireAgreement Significantly Expands Access to Phexxi® for Millions of Women Seeking an FDA-Approved, Hormone-Free, On-Demand Option to Prevent Pregnancy Long-term Contract Adds to Growing List of Agreements with Payers Opening New and Significant Access t
4y agoEVFMPhexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial DataPR NewswireThroughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis SAN DIEGO, June 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc ana
4y agoEVFMTraders News Source Interviews Evofem Biosciences, Inc. CEO Saundra PelletierACCESS NewswireNEW YORK, NY / ACCESSWIRE / June 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark R